Net Loss per Share

9 Months Ended

Sep. 30, 2026

Earnings Per Share [Abstract]

Net Loss per Share

Net Loss per Share

The following table shows total outstanding potentially dilutive shares excluded from the computation of diluted loss per share as their effect would be anti-dilutive, as of September 30, 2026 and 2025:

	September 30,
	2026	2025
	(in thousands)
Options to purchase common stock	3,108	3,739
Performance-based awards and restricted stock units	6,673	8,893
Employee stock purchase plan	84	88
Contingent consideration	312	—
Total	10,177	12,720

In March 2026, the Company finalized a post-closing working capital adjustment related to the acquisition of Foresight Diagnostics. Certain escrowed shares that were returned to the Company in the second quarter of 2026 have been excluded from the calculation of basic and diluted earnings per share.